Xylem and Partners Volunteer 157,000 Hours Toward Solving Water and Sustainability Challenges in 2022
Global water technology leader, Xylem (NYSE: XYL), reports that 87% of employees volunteered time in 2022, combining their efforts with volunteers from Xylem’s customers and partners around the world. The employee volunteers dedicated 157,000 hours during the year, an increase of 39% from 2021.
More than 15,600 employees participated in Xylem’s corporate social responsibility program, Xylem Watermark, in 2022, supporting a range of initiatives such as educating the next generation about critical water challenges, expanding access to safe water and sanitation, and supporting communities in crisis.
“Xylem Watermark is fundamental to our mission to solve the world’s biggest water challenges,” said Austin Alexander, Vice President of Sustainability and Social Impact at Xylem. “Our employees and partners showed remarkable commitment to solving short- and long-term water challenges in 2022, with 160 offices having 100% employee participation. We are proud of our teams and partners, who have already begun 2023 by volunteering in response to community needs, everywhere, including support for relief efforts and provision of fresh water to earthquake-affected regions of Turkey.”
“In 2022, our partnership with Xylem delivered clean water and sanitation to more than 2 million people affected by poverty or disaster,” said Rose Hogan, Interim Technical Unit Vice President at Americares. “Through the continued commitment of the Xylem team, we’ve provided water, sanitation, and hygiene education in India and Bangladesh, including infrastructure improvements and critical repairs in 27 health centers and six schools. We are incredibly proud of what we’ve achieved together in 2022.”
Employee’s volunteer efforts also contribute to Xylem’s 2025 Sustainability Goals, which include: providing access to clean water and sanitation for at least 20 million people; providing water and WASH (Water and Sanitation Hygiene) education for 15 million people; and giving 1% of profits and 1% of employee time to water-related causes and education.
In 2022, Xylem Watermark projects included:
- To support relief efforts in Ukraine, Xylem employees raised funds, hosted refugee families, collected supplies, donated equipment, and deployed emergency water treatment systems that serve 128,000 people.
- Xylem’s Humanitarian Disaster Response Team provided emergency water treatment systems in Ukraine, South Africa, Pakistan, and the Philippines.
- Employees raised water scarcity awareness and reduced water pollution through the global “Take Steps to Solve Water” campaign, featuring Manchester City manager Pep Guardiola.
- Partnering with NGO organizations including Americares, Engineers Without Borders, and Planet Water Foundation, Xylem Watermark supported the expansion of safe water and sanitation access to schools, hospitals, and communities, reaching 2.4 million people.
- Xylem Ignite continued to inspire future water leaders, with more than 1,200 students participating in the second annual Global Student Innovation Challenge and the Re-New Our World Challenge in the Middle East.
Xylem (XYL) is a leading global water technology company committed to solving critical water and infrastructure challenges with innovation. Our more than 17,000 diverse employees delivered revenue of $5.5 billion in 2022. We are creating a more sustainable world by enabling our customers to optimize water and resource management, and helping communities in more than 150 countries become water-secure. Join us at www.xylem.com.
About Xylem Watermark
Xylem Watermark, the Company’s corporate citizenship program, was initiated in 2008, with a focus on protecting and providing safe water resources around the world and also educating people on water-related issues. The global initiative, which encompasses employee and stakeholder engagement, provides access to clean drinking water and sanitation, and humanitarian emergency response to help communities become more water-secure and sustainable.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230220005154/en/
+1 (914) 240-3046
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
RevBio is Awarded a $2 Million Grant to Advance the Development of its Novel Dental Adhesive Bone Scaffold Product8.6.2023 00:12:00 EEST | Press release
RevBio, Inc., announced that it has been awarded a $2 million Phase II Small Business Innovation Research (SBIR) grant from the National Institute of Dental and Craniofacial Research (NIDCR), part of the National Institutes of Health (NIH). This funding (1R44DE032564-01) will allow the company to complete the pre-clinical research necessary to advance this product into the clinical stage of development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230607005794/en/ The current standard of care options for rebuilding deficient jawbone includes a variety of materials that require membranes and time consuming fixation devices. These products do not predictably maintain ridge volume which requires surgeons to undergo re-grafting in over 30% of clinical cases. TETRANITE eliminates the use of membranes and other fixation devices, when compared to the standard of care. Furthermore, TETRANITE resorbs fully while maintaining predict
IFF Names New President of Nourish and Introduces Leadership Structure Aligned to New Operating Model7.6.2023 23:18:00 EEST | Press release
IFF (NYSE: IFF) today announced that Yuvraj Arora, currently President, U.S. Categories for Kellogg North America, will join IFF as President, Nourish, effective June 19, 2023. Arora brings more than 25 years of multinational CPG experience to IFF’s Executive Leadership Team, mostly recently leading Kellogg’s $7 billion U.S. portfolio through a period of strong growth and portfolio transformation. IFF today also announced the leadership structure to support the transition to a new operating model as part of the company’s transformation strategy. The shift from its current divisional structure to three core end markets—Food and Beverage, Home and Personal Care, and Health—will provide greater customer intimacy and enhance cross-functional collaboration, allowing for enhanced execution, speed and streamlined delivery. IFF expects its new operating model to be in effect by the beginning of 2024. As President, Nourish, Arora, will lead IFF’s Food and Beverage categories when the operating
Vizgen Issues Open Letter to Customers and Researchers on 10x Genomics June 1, 2023 Lawsuit Announcement in Europe7.6.2023 22:00:00 EEST | Press release
Vizgen, Inc. (“Vizgen” or the “Company”), a life science leader dedicated to improving human health by visualizing single-cell spatial genomics information, today issued the below open letter to customers and researchers in response to 10x Genomics, Inc. (“10x”) filing a lawsuit on June 1, 2023 with the Unified Patent Court (“UPC”) in Europe. *** June 7, 2023 Dear Customers, Researchers and Friends of Vizgen: We are disappointed – though not surprised – that 10x has filed another lawsuit that attempts to undermine innovation, eliminate competition and intimidate both customers and industry peers. Although 10x’s UPC complaint is not yet available to us, we will keep you updated as we learn more. In the meantime, rest assured that we will vigorously defend our shared interests in all proceedings with the UPC, much like we have in the ongoing litigation in the U.S. District Court for the District of Delaware. In the Delaware case, we have gone on the offensive to assert our own countercla
Brenus Pharma announces its international Scientific Committee7.6.2023 19:00:00 EEST | Press release
Following the American Society of Clinical Oncology’s Annual Meeting, where Brenus’ innovative approach and promising preclinical results were featured in the abstract section “Treatment to Follow” 1, the company highlighted its international scientific committee. This committee gathering renowned international experts in immuno-oncology, immunotherapies, and novel-treatments is supporting Brenus’ scientific developments of the STCplatform pipeline in solid tumors and its first candidate, STC-1010 targeting colorectal cancer. The committee combined a total of over 1,700 internationally peer-reviewed articles and prestigious awards in the field: Pr François GHIRINGHELLI MD, PhD. Pr of Oncology – Head of “Cancer and adaptative immune response” INSERM, CGFL 2, Dijon. (FR) Head of the Board Pr Ahmad AWADA MD, PhD. Pr of Oncology – Head of Oncology medicine Dept. Jules Bordet Institute-HUB, Brussel. (BE) & Board member Oncodistinct clinical and translational research network, ESMO3 active m
Lunaphore and CST Partnership Advances Spatial Biology Research with Over 1,700 IHC-Validated Antibodies for Use on COMET™7.6.2023 17:00:00 EEST | Press release
Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, and Cell Signaling Technology (CST), a life science discovery technology company and leading provider of antibodies, kits, and services, today announced a partnership to enable the use of CST® antibodies on the Lunaphore COMET™ platform, a scalable hyperplex imaging solution for fully automated spatial biology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230607005502/en/ CST is a trusted provider of high-quality, rigorously validated antibodies for immunohistochemistry (IHC) that can detect key proteins in a variety of disease states. This partnership enables the use of over 1,700 IHC-validated antibodies from CST detected by fluorescent secondary antibodies for use on the COMET™, empowering researchers to develop antibody panels quickly and with confidence. With a comprehensive offering of primary rabbit and mous
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom